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We conducted a survey of pediatric infectious diseases provid-
ers in the Emerging Infections Network regarding the workup 
and treatment of children with Staphylococcus aureus bacter-
emia (SAB). We found significant practice variation in the man-
agement of children with SAB. These findings emphasize the 
need for further research to guide best practices.
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Staphylococcus aureus is a leading cause of bacteremia in chil-
dren; however, optimal management of these patients remains 
unclear [1, 2]. The Infectious Diseases Society of America 
(IDSA) guidelines for the treatment of methicillin-resistant 
S aureus (MRSA) bacteremia recommend vancomycin therapy 
for up to 6 weeks, depending on the source and clinical response 
[3]. Guidelines for the treatment of methicillin- susceptible 
S aureus (MSSA) bacteremia recommend nafcillin as first-line 
therapy, with cefazolin as an alternative [4].
Despite these recommendations, the application of broad 
guidelines to specific scenarios encountered in the manage-
ment of S aureus bacteremia (SAB) in children remains difficult. 
Recent literature has challenged long-held notions regarding 
optimal management of SAB associated with osteoarticular 
infections [5, 6]; however, there remains a paucity of evidence 
to guide management in several other common scenarios 
including the following: nonpersistent SAB without a source, 
prolonged MRSA bacteremia, and central-line associated SAB. 
Given the complexity in the management of children with SAB, 
we sought to describe practice patterns and clinical decision 
making among pediatric infectious diseases (PID) providers.
METHODS
From January to February 2017, we distributed a 7-question, 
electronic, vignette-based survey (Supplementary Data, https://
ein.idsociety.org/surveys/survey/100/) of clinical scenarios 
related to the management of SAB in children to PID providers 
in the Emerging Infections Network of the Infectious Diseases 
Society of America (IDSA EIN).
The survey questions explored diagnostic and treatment 
practices of providers for patients with osteomyelitis-associated 
SAB, nonpersistent SAB (<48 h), persistent MRSA bacteremia, 
peripherally inserted central catheter (PICC)-associated throm-
bosis with SAB, and parenteral treatment of choice for MSSA 
bacteremia.
Demographic information regarding practice region, expe-
rience, and employment was collected by EIN membership 
profile. Similar to previous EIN surveys, the response rate was 
calculated from PID EIN members who had ever responded to 
a survey [7, 8]. Descriptive statistics were calculated as percent-
ages for each response category.
RESULTS
Two hundred twenty-three of 334 (67%) clinicians with a PID 
practice responded from the United States and Canada, most 
(37%) having 5–14 years of clinical experience, and the majority 
practicing at a university hospital (62%). Fourteen (6%) provid-
ers do not manage children with SAB and were excluded from 
the analysis.
Osteomyelitis-Associated Staphylococcus aureus Bacteremia 
For children with osteomyelitis-associated SAB showing clini-
cal improvement shortly after initiation of antibiotics, almost all 
(97%) providers routinely repeat blood cultures until negative, 
whereas a minority routinely image the heart (29%), abdomen 
(3%), retina (6%), or vasculature (eg, Doppler ultrasound, 12%) 
(Figure 1A). Figure 1B shows the various treatment approaches 
taken by pediatric providers, with half (50%) treating intra-
venously only for those with persistent bacteremia (>48–72 
hours), whereas 28% treat almost all patients with 10–14 days of 
intravenous (IV) antibiotics and 22% treat with oral antibiotics 
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once they have clinically improved (ie, no minimum duration of 
parenteral therapy). For those with MSSA bacteremia, nafcillin 
and cefazolin are used similarly (Figure 1C).
Nonpersistent Staphylococcus aureus Bacteremia 
For febrile, well appearing children with only 1 S aureus blood 
culture, no clear source of infection, and subsequent negative 
cultures before antibiotics, 54% of providers treat with oral anti-
biotics after empiric vancomycin; 25% complete therapy with 
IV antibiotics, and 17% discontinue antibiotics, assuming that 
S aureus is a contaminant. A small proportion (4%) of providers 
chose an alternative management strategy, including evaluating 
for a source of infection (3%).
Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia
For the treatment of children with persistent MRSA bacteremia 
despite adequate vancomycin levels, 37% continue vancomycin 
and add a second agent, most commonly rifampin. A minority 
(12%) continue vancomycin monotherapy, whereas 43% change 
to other agents, most commonly daptomycin; 8% of providers 
chose an alternative management strategy.
Peripherally Inserted Central Catheter-Associated Thrombus With 
Staphylococcus aureus Bacteremia 
There was no consensus on the duration of IV therapy for chil-
dren with PICC-associated thrombus and bacteremia; 34% 
treated for 2 weeks, 37% treated for 4 weeks, 18% treated for 
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Figure  1. Practice patterns among providers for the workup and treatment of osteomyelitis-associated Staphylococcus aureus bacteremia (SAB). 
(A) Diagnostic workup for a child with osteomyelitis-associated SAB that is improving shortly after antibiotic initiation. Almost all providers repeat blood 
cultures until negative; however, the minority will routinely look for other foci of infection. (B) For the treatment of osteomyelitis-associated SAB, 50% of pro-
viders will switch to an oral regimen for nonpersistent bacteremia. Twenty-eight percent and 22% will treat with all intravenous antibiotics or treat with oral 
antibiotics after clinical improvement, respectively. (C) For the treatment methicillin-susceptible Staphylococcus aureus bacteremia with osteomyelitis, 55% of 
clinicians use nafcillin, 42% use cefazolin, and 3% use an alternative agent.
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6 weeks, and 11% chose an alternative treatment strategy. The 
majority (71%) recommend anticoagulation.
DISCUSSION
This study provides insights on the variation in the manage-
ment of children with S aureus bacteremia. Notably, we found 
very little agreement in (1) the optimal route of antibiotics for 
children with osteomyelitis-associated SAB and nonpersistent 
SAB, (2) choice of antibiotic for MSSA bacteremia, (3) antibi-
otic approach in children with persistent MRSA bacteremia on 
vancomycin, and (4) optimal duration of antibiotics for PICC-
associated thrombus and SAB.
These results highlight the complexity in caring for children 
with SAB and current gaps in consensus guidelines for the opti-
mal management of these patients. Clinicians often encounter 
scenarios with little data to support treatment decisions, or they 
are forced to extrapolate data from adult studies. In children 
with SAB, however, the mortality, pathophysiology, and antibi-
otic pharmacokinetics are quite different than adults [3, 9–11]. 
The IDSA guidelines for MRSA bacteremia recommend echo-
cardiography for all adult patients, whereas in children this is 
only recommended for those with congenital heart disease, 
persistent bacteremia (>48–72 hours), or clinical findings sug-
gestive of endocarditis. Our results reflect this recommenda-
tion because less than one third of providers routinely obtain 
an echocardiogram in a clinically improving child with SAB 
(Figure  1A). Notably, for a vignette describing bacteremia in 
a child with significant atopic dermatitis, 17% of respondents 
chose to discontinue antibiotics, assuming that S aureus was a 
contaminant—a recommendation at odds with the Committee 
on Infectious Diseases recommendation that “S. aureus almost 
never is a contaminant when isolated from a blood culture” [12]. 
Although it is certainly biologically plausible that a positive 
blood culture for S aureus could be a result of skin contamina-
tion, particularly in atopic dermatitis with or without cutaneous 
S aureus infection, there is historic precedent to treat these chil-
dren with a short course of parenteral antibiotics. Whether this 
is suitable in practice is thus far unstudied and merits further 
discussion in subsequent guideline revisions.
The optimal route of antibiotics for children with SAB is a 
scenario in which practice variation is high and is an area of 
ongoing research among PID specialists. There is a growing 
body of evidence, particularly in bacteremic osteoarticular 
infections, that an early switch to oral antibiotics is safe and 
does not increase the risk of treatment failure [5, 6]; however, 
many clinicians remain hesitant to adopt this practice due to the 
invasive nature of the infection and uncertainty of absorption/
penetration of some oral antibiotics. This study illuminates the 
need for ongoing investigation in this area.
The implications of practice variation in the management of 
children with SAB are numerous, including unnecessary diagnostic 
testing (eg, echocardiogram, visceral imaging), invasive proce-
dures (eg, PICC line insertion), and prolonged antibiotic exposure. 
Moreover, this variation leads to increased healthcare costs and 
risk of adverse effects. Identifying areas in which these variations 
exist provides an opportunity to improve the value of healthcare 
delivery and reduce costs without compromising patient care.
CONCLUSIONS
Our study has certain limitations. The response rate, although 
acceptable for this type of survey, may lead to sampling bias, and 
it may not be generalizable to all PID providers. However, there 
was an equal distribution of responders throughout most regions 
of the United States, which may limit this bias. In addition, 
responses to vignette-based questions may be subject to response 
bias, and we recognize that vignettes may only approximate what 
is actually done in clinical practice. Finally, the anonymity of the 
survey is designed to allow responders to answer questions as 
accurately as possible; however, survey answers may not accu-
rately reflect true practice patterns. Nevertheless, this study high-
lights the substantial variation in the management of children 
with SAB, can inform guidelines, and should guide our next steps 
in evaluating best practice patterns for this challenging pathogen.
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